Newest HIV Drugs Should Be Used With FUZEON(R)

Data presented at IAS build a compelling case for FUZEON (enfuvirtide, formerly known as T-20) to be combined with the newest drugs to give patients facing resistance their best chance of achieving undetectable viral load the optimal treatment goal for all people living with HIV. "Undetectable viral load should be the ultimate treatment goal for all triple-class experienced patients. FUZEON combined with the latest drugs now makes this much more achievable," explained Dr Mike Youle the Royal Free Hospital, London. "We are seeing a consistent FUZEON effect with these new drugs and I believe these data must change the way we manage triple class experienced patients facing HIV resistance and failing to reach undetectable viral load." Studies presented this week show that when FUZEON was given in combination with the novel HIV medication, tipranavir, an impressive 70% of FUZEON naïve patients achieved a ten-fold reduction in their viral load and furthermore they also had double the increase in immune cell count1, compared to patients receiving tipranavir/r without FUZEON.